A 6-year-old child developed heparin-induced thrombocytopenia while on extracorporeal life support. Hours after a difficult transition from heparin to argatroban for anticoagulation therapy, the child underwent heart transplantation. Intraoperative management was plagued with circuit thrombus formation while on cardiopulmonary bypass and subsequent massive hemorrhage after bypass. We review the child’s anticoagulation management, clinical challenges encountered, and review current literature related to the use of argatroban in pediatric cardiac surgery.
AlsoufiBBoshkovLKKirbyA. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2004;7:155-171.
2.
WarkentinTEGreinacherAKosterALincoffAM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):340S-380S.
3.
LinkinsLADansALMooresLK. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e495S-e530S.
4.
HantganRRJeromeWGHurstingMJ. No effect of clot age or thrombolysis on argatroban’s inhibition of thrombin. Blood. 1998;92:2064-2074.
5.
KosterAFischerK-GHarderSMertzlufftF. The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT. Biologics. 2007;1:105-112.
6.
SkrupkyLPSmithJRDealEN. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia. Pharmacotherapy. 2010;30:1229-1238.
7.
BöningAMorschheuserTBläseU. Incidence of heparin-induced thrombocytopenia and therapeutic strategies in pediatric cardiac surgery. Ann Thorac Surg. 2005;79:62-65.
8.
BoshkovLKKirbyAShenIUngerleiderRM. Recognition and management of heparin-induced thrombocytopenia in pediatric cardiopulmonary bypass patients. Ann Thorac Surg. 2006;81:S2355-S2359.
9.
HurstingMJDubbJVerme-GibboneyCN. Argatroban anticoagulation in pediatric patients: a literature analysis. J Pediatr Hematol Oncol. 2006;28:4-10.
10.
VakilNHKanaanAODonovanJL. Heparin-induced thrombocytopenia in the pediatric population: a review of current literature. J Pediatr Pharmacol Ther. 2012;17:12-30.
11.
AvilaMLShahVBrandaoLR. Systematic review on heparin-induced thrombocytopenia in children: a call to action. J Thromb Haemost. 2013;11:660-669.
12.
DhillonS. Argatroban: a review of its use in the management of heparin-induced thrombocytopenia. Am J Cardiovasc Drugs. 2009;9:261-282.
13.
MoffettBSTeruyaJ. Trends in parenteral direct thrombin inhibitor use in pediatric patients: analysis of a large administrative database. Arch Pathol Lab Med. 2014;138:1229-1232.
14.
MejakBGiacomuzziCShenIBoshkovLUngerleiderR. Cardiopulmonary bypass using argatroban as an anticoagulant for a 6.0-kg pediatric patient. J Extra Corpor Technol. 2005;37:303-305.
15.
CurversJvan de KerkhofDStroobantsAKvan den DoolEJScharnhorstV. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?Am J Clin Pathol. 2012;138:551-558.
16.
FritsmaGA. Monitoring the direct thrombin inhibitors. Clin Lab Sci. 2013;26:54-57.
17.
NhieuSNguyenLPretoriusV. CASE 1—2015: left ventricular assist device insertion in a patient with heparin-induced thrombocytopenia and renal failure. J Cardiothorac Vasc Anesth. 2015;29:210-220.
18.
AgarwalSUllomBAl-BaghdadiYOkumuraM. Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass. J Anaesthesiol Clin Pharmacol. 2012;28:106-110.
19.
CiccoloMLBernsteinJCollazosJC. Argatroban anticoagulation for cardiac surgery with cardiopulmonary bypass in an infant with double outlet right ventricle and a history of heparin-induced thrombocytopenia. Congenit Heart Dis. 2008;3:299-302.
20.
LoveJEFerrellCChandlerWL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost. 2007;98:234-242.
21.
MadabushiRCoxDSHossainM. Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. J Clin Pharmacol. 2011;51:19-28.
22.
YoungGBoshkovLKSullivanJE. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer. 2011;56:1103-1109.
23.
DykePCRussoPMureebeLRussoJTobiasJD. Argatroban for anticoagulation during cardiopulmonary bypass in an infant. Paediatr Anaesth. 2005;15:328-333.
24.
MalherbeSTsuiBCStobartKKollerJ. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology. 2004;100:443-445.
25.
AlmondCSDHarringtonJThiagarajanR. Successful use of bivalirudin for cardiac transplantation in a child with heparin-induced thrombocytopenia. J Heart Lung Transplant. 2006;25:1376-1379.
26.
DragomerDChalfantABiniwaleRReemtsenBFedermanM. Novel techniques in the use of bivalirudin for cardiopulmonary bypass anticoagulation in a child with heparin-induced thrombocytopenia. Perfusion. 2011;26:516-518.
27.
GatesRYostPParkerB. The use of bivalirudin for cardiopulmonary bypass anticoagulation in pediatric heparin-induced thrombocytopenia patients. Artif Organs. 2010;34:667-669.
28.
MurrayPTReddyBVGrossmanEJ. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int. 2004;66:2446-2453.
29.
KosterAChewDGründelM. An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesth Analg. 2003;96:1316-1319.
30.
GenzenJRFareedJHoppensteadtD. Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis. Transfusion. 2010;50:801-807.
31.
YoungGYonekawaKENakagawaPABlainRCLovejoyAENugentDJ. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis. 2007;18:547-553.
